肺纤维化分子治疗概况

Survey on molecular therapy of pulmonary fibrosis

肺纤维化是一种慢性、进行性、不可逆转的肺间质疾病,目前针对肺纤维化尚没有确切的治疗方法,在肺纤维化的发生、发展过程中有多种炎性因子和细胞因子参与其中,并通过不同的信号通路发挥其致病作用,近年来不少研究发现通过调控相关细胞因子、NLRP3炎症小体、microRNA,可有效抑制肺纤维化的进程,改善肺部纤维化。因此针对肺纤维化的分子治疗有助于新药物靶标的发现和治疗药物的开发,为肺纤维化的治疗提供可能。

Pulmonary fibrosis is a chronic,progressive,irreversible pulmonary interstitial diseases,for the treatment of pulmonary fibrosis are not exact. A variety of inflammatory factors and cytokines involve in the process of the occurrence and development of pulmonary fibrosis,and play a role of the disease through different signaling pathways. In recent years,many studies have found that by regulating related cytokines,inflammatory corpuscle NLRP3,microRNA,can effectively inhibit the process of pulmonary fibrosis,and improve pulmonary fibrosis. Therefore,molecular therapy for pulmonary fibrosis is conducive to the discovery of new drug targets and the development of therapeutic drugs,providing the possibility for the treatment of pulmonary fibrosis.